



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 03/30/2020 13:00
Last Report Issued 09/13/2011 08:13

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 3157U
Patient ID 3157U
Chain 11002013
Age Not Given DOB Not Given
Gender Not Given
Workorder 11002013
Received 09/13/2011 08:05

Sample ID 11002013-001
Matrix Urine
Patient Name 3157U
Patient ID 3157U
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes

3157U Cotinine and Anabasine from Secondary Exposure, Urine

Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)

Cotinine None Detected ng/mL 1.0
Synonym(s): Nicotine Metabolite

Reported urine Cotinine concentrations:
<5 ng/mL in non-smokers with no secondary smoke exposure, 5 - 50 ng/mL in non-smokers with secondary exposure to smoke, <50 ng/mL in abstinent smokers following a 2 week abstinence.

Anabasine None Detected ng/mL 1.0

The presence of anabasine in urine is consistent with tobacco product use. Anabasine concentrations in the urine of tobacco users are much lower than cotinine concentrations. Anabasine is not present in nicotine replacement therapy products such as transdermal patches, gum, nasal sprays and inhalers.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.